Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and three...read more
UroGen Pharma, which is developing gel-based chemotherapies to treat urological cancers, raised $58 million by offering 4.5 million shares at $13, within the range of $12 to $14. . It originally planned to offer 3.5 million shares and raised 29% more in proceeds...read more
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and...read more
UroGen Pharma, which is developing formulations of a chemotherapy to treat urological cancers, announced terms for its IPO on Monday. It also added two underwriters in the filing. Insiders are purchasing $20 million of shares on the offering. The...read more
US IPO Weekly Recap: Biotechs and energy fail to excite in 5-IPO week
Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and three...read more
UroGen Pharma prices upsized IPO at $13 midpoint
UroGen Pharma, which is developing gel-based chemotherapies to treat urological cancers, raised $58 million by offering 4.5 million shares at $13, within the range of $12 to $14. . It originally planned to offer 3.5 million shares and raised 29% more in proceeds...read more
US IPO Week Ahead: May starts strong with 6 IPOs featuring energy and biotech
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and...read more
Chemotherapy biotech UroGen Pharma sets terms for $45 million IPO
UroGen Pharma, which is developing formulations of a chemotherapy to treat urological cancers, announced terms for its IPO on Monday. It also added two underwriters in the filing. Insiders are purchasing $20 million of shares on the offering. The...read more